Article Abstract

Evaluation of combined anti-PD-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis

Authors: Derek Nichols, Theresa A. Boyle, David Noyes, Kujtim Latifi, Vladimir Feygelman, Isabel Jackson, Zeljko Vujaskovic, Scott Antonia, Bradford A. Perez


Outcomes for patients with inoperable locally advanced non-small cell lung cancer (LA-NSCLC) are poor, with a median survival of about 2 years (1) and a 5-year survival of about 10–15% following diagnosis, even among patients with good performance status at presentation (2). Despite these poor outcomes, conventional radiation therapy (RT) with chemotherapy remains the standard of care.

Article Options

Download Citation